BERENICE

Benznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas diseasE

Coordinatore	INSTITUT CATALA DE LA SALUT    more  Organization address address: GRAN VIA DE LES CORTS CATALANES 587 city: BARCELONA postcode: 8007 contact info Titolo: Dr. Nome: Joan X Cognome: Comella Email: send email Telefono: 34934894013
Nazionalità Coordinatore	Spain [ES]
Totale costo	3˙989˙937 €
EC contributo	2˙998˙217 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-09-01   -   2017-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	INSTITUT CATALA DE LA SALUT  Organization address address: GRAN VIA DE LES CORTS CATALANES 587 city: BARCELONA postcode: 8007 contact info Titolo: Dr. Nome: Joan X Cognome: Comella Email: send email Telefono: 34934894013	ES (BARCELONA)	coordinator	933˙104.40
2	"CENTRO DE INVESTIGACION BIOMEDICA EN RED BIOINGENIERIA, BIOMATERIALES Y NANOMEDICINA"  Organization address address: CALLE POETA MARIANO ESQUILLOR city: ZARAGOZA postcode: 50018 contact info Titolo: Dr. Nome: Jesús Cognome: Izco Email: send email Telefono: 34679490537 Fax: 34976512368	ES (ZARAGOZA)	participant	557˙145.70
3	FUNDACAO OSWALDO CRUZ  Organization address address: AVENIDA BRASIL 4365 city: RIO DE JANEIRO postcode: 21040 900 contact info Titolo: Prof. Nome: Rodrigo Cognome: Corrêa-Oliveira Email: send email Telefono: +55 31 3349 7701	BR (RIO DE JANEIRO)	participant	341˙900.00
4	INSTITUTO DE HIGIENE E MEDICINA TROPICAL  Organization address address: Rua da Junqueira 100 city: LISBOA postcode: 1349-008 contact info Titolo: Dr. Nome: Marcelo Sousa Cognome: Silva Email: send email Telefono: +351 21 365 26 Fax: +351 21 363 21 05	PT (LISBOA)	participant	280˙000.00
5	UNIVERSITAT DE BARCELONA  Organization address address: GRAN VIA DE LES CORTS CATALANES 585 city: BARCELONA postcode: 8007 contact info Titolo: Mr. Nome: Xavier Cognome: Gutierrez Email: send email Telefono: +34 934035385 Fax: +34 934489434	ES (BARCELONA)	participant	250˙999.92
6	ADMINISTRACION NACIONAL DE LABORATORIOS E INSTITUTOS DE SALUD DR. CARLOS G. MALBRAN  Organization address address: Avenida Velez Sarsfield 563 city: BUENOS AIRES postcode: 1281 contact info Titolo: Mr. Nome: Ezequiel Cognome: Cravero Email: send email Telefono: +54 11 4343 3965 Fax: +54 11 4343 3965	AR (BUENOS AIRES)	participant	234˙400.00
7	"LABORATORIO ELEA SOCIEDAD ANONIMA COMERCIAL, INDUSTRIAL, FINANCIERA Y AGROPECUARIA"  Organization address address: SANABRIA 2353 city: BUENOS AIRES postcode: C1417AZE contact info Titolo: Mr. Nome: Luis Cognome: Ferrero Email: send email Telefono: 541144000000 Fax: 54143794298	AR (BUENOS AIRES)	participant	205˙369.00
8	PRAXIS PHARMACEUTICAL FRANCE SARL  Organization address address: AVENUE PAUL DOUMER 147 city: RUEIL MALMAISON postcode: 92500 contact info Titolo: Mr. Nome: Pinhas Cognome: Melul Email: send email Telefono: 33175610390 Fax: 33175610396	FR (RUEIL MALMAISON)	participant	195˙298.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The BERENICE consortium is aiming at providing a new and cost-effective solution to a better treatment for Chagas chronic patients. Please see its objectives below :

Main objective • Obtain a more effective, better tolerated and cheaper formulation of a drug with trypanocidal activity to cure Chagas disease

Specific Objectives • Obtain results of pharmacokinetics of new formulations • Assess trypanocidal activity of new formulations in vitro and in animal model • Involve partners, research and industry in endemic countries to promote technology transfer and promote in-site solutions at cheaper cost. The foreseen results of this project would have firstly an impact on the better comprehension and control of the SUVs behavior as drug delivery nanodevices for the specific APIs to be conjugated. If this conjugation is successful, further impacts are expected dealing with technology transfer issues, such as scale-up of the corresponding SUVs preparation methodology and its implementation at industrial scale. Apart from including stong participation from endemic countries's institutions, the consortium also involves private companies, thus enabling the participation of all the key actors of the chain to confront and control better Chagas disease. The innovative approach, through the new developed nano- and microparticles based formulations will have an important impact on the safety of the medicament since the therapeutic efficacy will increase and consequently the doses needed and the incidences caused by adverse effects will be reduced.'

Introduzione (Teaser)

Millions of people worldwide are infected with Chagas' disease. Obtaining proper drug formulations should improve therapeutic outcome and minimise side-effects.